An AMPH-truncation protein for the detection of amphipathic protein autoantibodies in neurological paraneoplastic syndromes and its application
By segmenting the AMPH protein into truncation sites and screening for the AMPH-3-2 (300-360aa) antigen fragment, combined with cell substrate detection, the sensitivity and specificity issues of AMPH autoantibody detection have been resolved, enabling efficient early diagnosis of tumors and neurological diseases.
Patent Information
- Application Number
- CN202611623422.3
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2026-10-20
- Publication Date
- 2026-11-17
AI Technical Summary
Existing AMPH autoantibody detection technologies suffer from unclear antigen epitopes, insufficient detection sensitivity, poor specificity, and weak correlation with clinical symptoms, making accurate diagnosis of tumors, cancers, and neurological symptoms difficult.
By selectively truncating the full-length AMPH protein, AMPH-3-2 (300-360aa) was selected as a specific antigen fragment for detection. It was then expressed in eukaryotic cells and detected using the cell substrate method (CBA method) to ensure the effectiveness of the protein's native conformation and the antigenic epitope.
It significantly improves the detection sensitivity and specificity of AMPH autoantibodies, provides support for early screening of tumors and monitoring of neurological diseases, addresses the shortcomings of traditional detection technologies, and achieves efficient clinical diagnosis.
Smart Images

Figure CN123106872A_ABST
Abstract
Description
Technical Field
[0001] This invention relates to an AMPH truncated protein for detecting amphiphilic protein (AMPH) autoantibodies in paraneoplastic syndromes of the nervous system and its application. Specifically, it relates to an AMPH truncated protein for detecting amphiphilic protein (AMPH) autoantibodies in paraneoplastic syndromes of the nervous system (PNS), and the application of the truncated protein in the preparation of PNS-related diagnostic reagents, belonging to the field of autoantibody detection technology. Background Technology
[0002] Paraneoplastic neurological syndromes (PNS) are autoimmune neurological disorders caused by cross-immune reactions induced by tumor-associated antigens. High-risk paraneoplastic autoantibodies (such as Hu, Ri, and Yo) are highly correlated with the occurrence of malignant tumors and have important clinical value in early identification, tumor screening, and prognostic assessment. The updated diagnostic criteria in 2022 further clarified the classification and risk stratification significance of high-risk antibodies; therefore, the high sensitivity and high specificity of high-risk paraneoplastic antibody detection are of great clinical significance.
[0003] Amphiphysin (AMPH) is an intracellular protein located in vesicles on the presynaptic membrane of neurons. It participates in the release and reuptake of neurotransmitters during depolarization. AMPH also participates in the formation of cell membrane curvature. When AMPH is recognized by autoantibodies, it leads to impaired synaptic vesicle reuptake, weakened vesicle endocytosis, and inhibition of neurotransmitter release from the presynaptic neuron. Studies show that human AMPH protein consists of 695 amino acids, mainly composed of three domains: the N-terminal BAR domain, the middle clathrin-binding domain (CLAP), and the C-terminal SH3 domain.
[0004] AMPH is an intracellular protein, but unlike classic paraneoplastic antigens (HuD, Ri, Yo, etc.), it is classified as an intermediate antigen because it is transiently exposed to the extracellular space during the fusion of vesicles with nerve cell membranes. This exposure can allow autoantibodies to bind to it and produce pathogenic effects. Patients with AMPH autoantibody-positive paraneoplastic syndromes who also have neurological disorders typically present with stiff-person syndrome, encephalomyelitis, or peripheral neuropathy. Furthermore, over 80% of patients with positive AMPH autoantibodies also have breast cancer and small cell lung cancer, classifying them as high-risk paraneoplastic autoantibodies.
[0005] The antigenic target sites of AMPH autoantibodies exhibit significant diversity. David et al. found that the N-terminal and C-terminal regions of the AMPH protein are highly conserved between chickens and humans. Further research revealed that autoantibodies from stiff-person syndrome patients primarily target the C-terminal region containing the SH3 domain. To further precisely locate the antigenic epitopes of AMPH autoantibodies, Saiz et al. constructed five AMPH protein truncated fragments and performed immunoblotting reactions with serum from small cell lung cancer patients. The results showed that the serum of nine positive patients reacted with the C-terminal fragment of AMPH, but the serum of seven positive patients still targeted the remaining four AMPH truncated fragments to varying degrees. Furthermore, Floyd et al., based on experiments with mouse anti-human AMPH monoclonal antibodies, found that only three of the 30 monoclonal antibodies produced by immunization targeted the C-terminal SH3 region.
[0006] The above study preliminarily revealed the distribution characteristics of AMPH autoantibody epitopes, but it also showed that the diversity of antibody targets of AMPH autoantibodies will seriously interfere with the specific diagnosis of tumors and cancers and the accurate classification of neurological syndromes. That is, some autoantibodies targeting certain targets may not have clinical diagnostic significance. Therefore, it is necessary to screen effective antigen targets with clinical diagnostic significance.
[0007] Current methods for detecting AMPH autoantibodies primarily employ immunoblotting. A study by Qiao Lei et al. showed that using Western blotting to detect AMPH autoantibodies resulted in 13 positive cases out of 15,000 suspected patients, a detection rate of 0.087%. Kunchok et al. from Mayo Clinic also used Western blotting to detect AMPH autoantibodies, finding only 2 positive cases in the serum of 22,472 suspected adult patients. As mentioned earlier, AMPH, as an intermediate antigen possessing both intracellular and extracellular protein characteristics, largely depends on its membrane protein-like topology, requiring high precision in conformational formation and maintenance. Immunoblotting is only suitable for detecting linear epitopes; it suffers from systematic loss of conformation-dependent epitopes, leading to low sensitivity and specificity, thus posing significant limitations in AMPH autoantibody detection.
[0008] Cell Binding Assay (CBA) involves transfecting exogenous target genes into cells, causing the cells to express their own antigens, and then using these antigens as substrates to detect autoantibodies via cellular immunofluorescence. Since the target protein is expressed in eukaryotic cells: (1) it maximizes the efficient expression of the protein, significantly increasing its abundance; (2) it maximizes the correct folding and assembly of the protein, forming a functional topological structure; and (3) it maximizes the replication of the protein's microenvironment (niche) in vivo, including suitable pH and ion concentrations, simulating the protein's actual state in vivo. Based on this, CBA detection can more accurately reflect the binding of autoantibodies to antigenic epitopes in vivo, significantly improving the sample detection rate.
[0009] Therefore, it is essential to develop a protein for the detection of AMPH autoantibodies in humans and its application. This method can: (1) reveal the distribution of antigenic epitopes of AMPH autoantibodies while maintaining their native conformation; (2) improve the detection sensitivity and specificity of AMPH autoantibodies; and (3) discover the correlation between AMPH autoantibodies targeting specific sites and tumor formation and neurological symptoms. Summary of the Invention
[0010] This invention aims to address the technical shortcomings of existing AMPH autoantibody detection technologies, such as unclear antigen epitopes, insufficient detection sensitivity, poor specificity, and weak correlation with clinical symptoms. It provides an AMPH truncated protein for the detection of amphipathic protein autoantibodies in neurological paraneoplastic syndromes and its applications. This invention, through targeted truncation site segmentation and systematic screening of the full-length AMPH protein, identifies the AMPH truncated protein with the amino acid sequence shown in SEQ ID NO: 11 as the detection-specific antigen fragment. This meets the clinical diagnostic needs of neurological paraneoplastic syndromes and other antibody-related diseases, providing strong support for early screening, diagnosis, and disease monitoring, filling gaps in existing detection technologies, and promoting the improvement of diagnosis and treatment of related autoimmune diseases.
[0011] The present invention is achieved through the following technical solution: an AMPH truncated protein for detecting amphipathic protein autoantibodies in paraneoplastic syndromes of the nervous system, wherein the AMPH truncated protein is a CLAP domain truncated form of the AMPH protein, and its amino acid sequence is shown in SEQ ID NO: 11.
[0012] The present invention also provides a nucleic acid molecule that encodes the above-mentioned AMPH truncated protein.
[0013] And a recombinant expression vector comprising the above-mentioned nucleic acid molecules.
[0014] And a recombinant host cell comprising the above-mentioned recombinant expression vector, or wherein the above-mentioned nucleic acid molecules are integrated into a chromosome.
[0015] The present invention also provides the application of the above-mentioned AMPH truncated protein in the preparation of a diagnostic reagent for detecting amphiphilic protein autoantibodies in paraneoplastic syndromes of the nervous system, wherein the diagnostic reagent detects amphiphilic protein autoantibodies by a cell substrate method.
[0016] Preferably, the paraneoplastic syndrome of the nervous system includes one or more of stiff-person syndrome, encephalomyelitis, or peripheral neuropathy.
[0017] The present invention also provides a kit for detecting amphipathic protein autoantibodies in paraneoplastic syndromes of the nervous system, comprising the above-mentioned AMPH truncated protein.
[0018] Preferably, the kit detects amphipathic protein autoantibodies using the cell substrate method (CBA method).
[0019] Compared with the prior art, the present invention has the following advantages and beneficial effects: (1) This invention, through the design of specific cutoff sites, screens out the most important autoantigen epitope fragment with clinical diagnostic significance and capable of mediating autoimmune responses, and identifies it as the specific antigen fragment for detection. This fragment is a CLAP domain cutoff of the AMPH protein, and its amino acid sequence is shown in SEQ ID NO: 11. It can match clinically significant autoantibodies, thus solving the problems of weak specificity, insufficient sensitivity, and poor specificity of traditional antigen fragments from the source. Unlike the five AMPH cutoffs constructed by Saiz et al. in the prior art (whose reactivity with serum was only verified by immunoblotting), this invention, through systematic screening and functional verification, has identified the cutoff sequence with the best diagnostic performance in CBA method detection, greatly improving the detection accuracy and providing core technical support for AMPH autoantibody detection.
[0020] (2) The present invention achieves eukaryotic expression through the cell substrate method (CBA method), which maintains the native conformation of AMPH truncated protein to the greatest extent and significantly improves detection sensitivity and specificity.
[0021] (3) This invention provides a reliable basis for early screening and diagnosis of tumors such as small cell lung cancer and breast cancer related to AMPH antibodies; it can also provide quantitative support for disease classification, disease progression assessment, treatment plan adjustment and efficacy judgment of nervous system diseases such as stiff person syndrome and encephalitis, making up for the shortcomings of traditional detection in disease monitoring and improving the whole process of diagnosis and treatment.
[0022] (4) In this invention, the AMPH truncated protein is a CLAP domain truncated variant, containing the dominant antigenic epitope region of the CLAP domain, but removing regions that may introduce non-specific reactions, such as the BAR domain and the C-terminal SH3 region. Through the innovative truncated site design, the limitations of existing technologies are overcome, avoiding the false positive problem caused by the diversity of antigenic targets in the full-length protein, while retaining the effectiveness of the AMPH antigenic epitope, achieving an optimal balance between sensitivity and specificity. Attached Figure Description
[0023] Figure 1 This is a schematic diagram of the human AMPH protein domain and the AMPH fragment disclosed in this invention for use in autoantibody detection.
[0024] Figure 2 This is a blot image showing the detection results of a foreign blot reagent kit on a human AMPH-positive sample.
[0025] Figure 3 Fluorescence chromatograms of different truncated AMPH protein fragments in human AMPH-positive samples detected using the CBA methodology.
[0026] Figure 4 Fluorescence chromatogram of nonspecific results for detecting AMPH-3 truncated protein fragments in human AMPH-negative samples based on the CBA methodology.
[0027] Figure 5 Fluorescence chromatograms of human AMPH-negative and positive samples detected using the CBA methodology for the AMPH-3-2 truncated protein fragment. Detailed Implementation
[0028] The invention's objective, technical solution, and beneficial effects will be further explained in detail below.
[0029] It should be noted that the following detailed descriptions are exemplary and intended to provide further illustration of the claimed invention. Unless otherwise stated, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention pertains.
[0030] This invention relates to an AMPH truncated protein for the detection of amphipathic protein autoantibodies in paraneoplastic syndromes (PNS) and its application. The AMPH truncated protein is AMPH-3-2, a CLAP domain truncated variant of the AMPH protein, corresponding to amino acid residues 300-360 of the AMPH protein, and its amino acid sequence is shown in SEQ ID NO: 11. This invention re-divides the full-length AMPH protein by targeting specific truncated sites, designing nine truncated variants covering different domains of the AMPH protein, including the full-length variant. After targeting and exclusion experiments, AMPH-3-2 was finally selected as the specific antigen fragment for detection. This invention also provides a nucleic acid molecule encoding this truncated protein, the nucleotide sequence of which is shown in SEQ ID NO: 12; a recombinant expression vector containing this nucleic acid molecule; a recombinant host cell; and the application of this truncated protein in the preparation of diagnostic reagents and kits for PNS-related AMPH autoantibodies, with the preferred detection method being the cell substrate method (CBA method).
[0031] The core of the technical solution of this invention lies in: (1) Through the innovative design of the cut-off site, the existing technology has overcome the limitations of the understanding of the distribution of AMPH antigenic epitopes. By screening specific antigen fragments through a novel cut-off division, the problem of false positives in full-length protein detection is avoided, while the structural integrity of AMPH and the effectiveness of antigenic epitopes are preserved, thereby improving the sensitivity and specificity of autoantibody detection.
[0032] See Figure 1 Existing research indicates that the AMPH protein structure can be divided into three functional domains: the N-BAR domain, the CLAP domain, and the SH3 domain. David et al. revealed that AMPH autoantibodies primarily target the C-terminal region containing the SH3 domain. Saiz et al. constructed five AMPH truncated variants and verified their reactivity with serum using immunoblotting. Floyd et al. found that only three out of 30 monoclonal antibodies targeted the C-terminal SH3 region. However, these studies only preliminarily revealed the distribution trends of antigenic epitopes and did not determine which targets have clear clinical diagnostic significance, nor did they address the interference of antigenic target diversity on diagnostic specificity.
[0033] This invention is the first to systematically redivide the truncation sites for full-length AMPH proteins, designing nine truncation moduli covering the N-BAR domain, CLAP domain, and SH3 domain. The domain assignments, truncation sites, and serial numbers of each truncation moduli are shown in Table 1.
[0034] Table 1. Domain division and sequence numbering of the full-length AMPH protein truncated body.
[0035] This invention further validated the AMPH-3-2 (300-360aa) sequence from the nine newly designed truncated variants through targeting and exclusion experiments. This sequence, located within the CLAP domain, demonstrates its effectiveness as a specific antigen fragment for AMPH autoantibody detection, a phenomenon not previously revealed in existing technologies.
[0036] Specifically, the amino acid sequence of AMPH-3-2:300-360aa described in this invention comprises a natural amino acid sequence, a variant with high homology to the natural sequence (e.g., ≥80%, preferably ≥90%), and a functional fragment containing its key antigenic epitopes. These sequences can be chemically modified as necessary (e.g., covalent modification or isotopic labeling, such as methylation, glycosylation, phosphorylation, acetylation, hydroxylation, etc.) to suit CBA and immunoblotting detection, provided that the modification does not significantly affect its binding activity with AMPH antibodies.
[0037] (2) By combining the above-mentioned truncation strategy with the CBA method, the present invention expresses the AMPH-3-2 truncated protein in eukaryotic cells and detects it by the CBA method. This not only maintains the native conformation of the truncated protein by utilizing the eukaryotic expression system, but also provides a domain with clinical diagnostic significance through the truncation strategy. This avoids the false positive problem caused by the diversity of antigen targets of the full-length protein, as well as the problem of low detection rate of AMPH autoantibodies by existing immunoblotting methods, and significantly improves the detection sensitivity and specificity.
[0038] The technical solution of this invention can be further summarized in detail as follows: The present invention provides an AMPH truncated protein, wherein the truncated protein is AMPH-3-2 (300-360aa, as shown in SEQ ID NO: 11) identified from a novel truncated segment as a specific antigen fragment for detection, and further provides a nucleic acid molecule encoding the above-mentioned AMPH-3-2, a recombinant expression vector containing the nucleic acid molecule, and a recombinant host cell containing the above-mentioned recombinant expression vector or a chromosome in which the above-mentioned nucleic acid molecule is integrated.
[0039] More specifically, the nucleic acid sequence of the nucleic acid molecule is shown in SEQ ID NO: 12. This nucleic acid molecule can be its complementary sequence, or a nucleotide sequence with at least 80% homology that encodes the antigen. The recombinant expression vector can be a commonly used protein expression vector, such as pCDNA3.1(+), pCMV, or pENTER, preferably pCDNA3.1(+). The recombinant host cell can be a common protein-expressing cell line, such as HEK293 cells, CHO cells, or their derivative cell lines. The transfection reagents used include Lipo 3000 and PEI reagents, preferably 25 kDa PEI reagent. Furthermore, the transfection concentration is controlled between 500 and 4000 µg / mL, for example, 700 µg / mL, 1000 µg / mL, 1500 µg / mL, 2000 µg / mL, 2500 µg / mL, 3500 µg / mL, or 3800 µg / mL.
[0040] This invention also provides the application of the above-mentioned AMPH truncated protein in the preparation of a diagnostic reagent for detecting amphipathic protein (AMPH) autoantibodies in paraneoplastic syndromes (PNS), using a cell substrate assay (CBA method). The PNS includes one or more of stiff-person syndrome, encephalomyelitis, or peripheral neuropathy.
[0041] Specifically, it refers to a detection reagent or kit for using the AMPH truncated protein in a cell substrate assay (CBA method), wherein the detection reagent can be obtained by gene transfection technology to obtain a cell line overexpressing the AMPH truncated protein. Alternatively, it refers to a detection reagent or kit for using the AMPH truncated protein in an immunoblotting method, wherein the detection reagent can be obtained by gene transfection technology to obtain cells overexpressing the AMPH truncated protein.
[0042] The specific implementation of the present invention will be described below with reference to the embodiments. Of course, the scope of protection of the present invention is not limited to the following embodiments.
[0043] The experimental materials involved in the following embodiments include: Restriction endonuclease XbaI (NEB, catalog number R0145V); Restriction endonuclease NheI (NEB, catalog number R3131V); Restriction endonuclease NotI (NEB, catalog number R0189V); Restriction endonuclease BamHI (NEB, catalog number R0136V); Restriction endonuclease EcoRI (NEB, catalog number R0101V); High-fidelity DNA polymerase (Novizan, catalog number P505); One Step Cloning Kit (Novizan, catalog number C117-01); Restriction endonuclease NotI (NEB, catalog number R3189V); Slides (Mervide); High Affinity Ni-Charged Resin FF (Genscript, catalog number L00666-5); High-glucose DMEM (Gibco, catalog number 11965092); 10% fetal bovine serum (Gibco, catalog number 10099158); Anti-human Alexa 488 secondary antibody (Thermo Fisher Scientific, catalog number A20000); all primers were synthesized by Shanghai Jereh Biotechnology Co., Ltd.; the initial vector pcDNA3.1(+) was a conventional vector provided by Shaoxing University (Shaoxing College of Arts and Sciences).
[0044] Example 1: Construction of AMPH truncated variant overexpressing cell line This embodiment aims to construct nine truncated variants (including the full-length variant) covering different domains of the AMPH protein, and transfect them into HEK-293 cells to obtain cell lines overexpressing each truncated variant, providing antigen substrates for subsequent CBA assay.
[0045] (a) Obtaining the AMPH gene fragment Based on the protein domains of AMPH, the protein structure of AMPH was designed as multiple truncated gene fragments with different functional domains: including full-length AMPH: 1-695 aa, AMPH-1: 1-121 aa, AMPH-2: 122-250 aa, AMPH-3: 251-400 aa, AMPH-3-1: 251-310 aa, AMPH-3-2: 300-360 aa, AMPH-3-3: 350-400 aa, AMPH-4: 401-550 aa, and AMPH-5: 551-695 aa.
[0046] The specific construction steps are as follows: (1) Linearize the expression vector by XbaI single enzyme digestion.
[0047] (2) The pcDNA6TR vector was amplified using primers MCS-Myc-F / BGH-CX-R to obtain the myc-6×His tag sequence fragment.
[0048] (3) The linearized vector obtained in step (1) and the tag sequence fragment obtained in step (2) are homologously recombined using OneStep Cloning Kit to construct a new vector pCDNA3.1NS-mycHis.
[0049] (4) The pCDNA3.1NS-mycHis vector was digested with NheI and NotI.
[0050] (5) Amplify each AMPH truncated fragment using the following primer pairs: The full-length AMPH fragment was amplified using primers 3.1NS-AMPH-F / 3.1NS-AMPH-R. The AMPH-1 fragment was amplified using primers 3.1NS-AMPH-F / 3.1NS-AMPH-1-R; The AMPH-2 fragment was amplified using primers 3.1NS-AMPH-2-F / 3.1NS-AMPH-2-R; The AMPH-3 fragment was amplified using primers 3.1NS-AMPH-3-F / 3.1NS-AMPH-3-R; The AMPH-3-1 fragment was amplified using primers 3.1NS-AMPH-3-F / 3.1NS-AMPH-3-1-R; The AMPH-3-2 fragment was amplified using primers 3.1NS-AMPH-3-2-F / 3.1NS-AMPH-3-2-R; The AMPH-3-3 fragment was amplified using primers 3.1NS-AMPH-3-3-F / 3.1NS-AMPH-3-R; The AMPH-4 fragment was amplified using primers 3.1NS-AMPH-4-F / 3.1NS-AMPH-4-R; The AMPH-5 fragment was amplified using primers 3.1NS-AMPH-5-F / 3.1NS-AMPH-R.
[0051] The primer sequences are shown in Table 2.
[0052] Table 2 Primer Sequences
[0053] (6) The double-digested vector obtained in step (4) and the fragments obtained in step (5) are homologously recombined using One Step Cloning Kit to construct the full-length AMPH, AMPH-1, AMPH-2, AMPH-3, AMPH-3-1, AMPH-3-2, AMPH-3-3, AMPH-4, and AMPH-5, respectively.
[0054] (II) Construction of HEK293 cell line overexpressing AMPH truncated variant (1) Soak the glass slide in 75% ethanol, clean it with PBS phosphate buffer, and treat it with laminin at 37°C for 30 min.
[0055] (2) HEK-293 cells were cultured at 3.5 × 10⁻⁶. 5 Density seeding is applied to the glass slides prepared in the first step.
[0056] (3) After culturing for 24 hours, the full-length AMPH, AMPH-1, AMPH-2, AMPH-3, AMPH-3-1, AMPH-3-2, AMPH-3-3, AMPH-4 and AMPH-5 plasmids (transfection concentration 2000 µg / mL) were transfected into the cells using 25 kDa PEI reagent.
[0057] (4) After 6 hours, change the medium to HEK-293 cell culture medium (DMEM medium containing 10% fetal bovine serum) and continue culturing for 36-48 hours before subsequent detection.
[0058] Example 2: Application of AMPH truncated variant overexpressing cell lines in CBA assay This embodiment aims to use the AMPH truncated variant overexpressing cell lines obtained in Example 1 as detection reagents to perform immunofluorescence detection on clinical serum samples using the cell substrate method (CBA method), to evaluate the detection sensitivity and specificity of different truncated variants against AMPH autoantibodies, and to screen out the optimal antigen fragment.
[0059] (a) Detection methods In this embodiment, the antigen-overexpressing cell line obtained in Example 1 is used as a detection reagent, or included in a detection kit, to perform the following detection process: (1) The antigen composition overexpressing cell line obtained 36-48 hours after transfection was fixed with acetone for 10 min.
[0060] (2) Collect serum from healthy individuals and patients and dilute them at a ratio of 1:10.
[0061] (3) Mix the diluted serum with the cells treated in (1) and incubate at 37°C for 60 min.
[0062] (4) After incubation, rinse with PBS 3 times, 5 min each time.
[0063] (5) Incubate with the anti-human Alexa 488 secondary antibody and the incubation product in (4) at 37°C for 30 min.
[0064] (6) After incubation, rinse with PBS three times, each time for 5 minutes.
[0065] (7) Observe and photograph under a fluorescence microscope.
[0066] (II) Analysis of Test Results The AMPH truncated variant overexpressing cell line obtained in Example 1 was used as a detection reagent to perform immunofluorescence detection on normal human serum samples and AMPH-positive serum samples, and the detection results were analyzed.
[0067] (1) AMPH positive sample test results (see Table 1, Figure 2 and Figure 3 ) Using a foreign blot kit and different AMPH truncated cell lines overexpressing AMPH, 10 AMPH-positive samples (clinically presenting as stiff-person syndrome, encephalomyelitis or peripheral neuropathy, accompanied by small cell lung cancer or breast cancer) were tested based on the CBA methodology. The results are shown in Table 3.
[0068] Table 3. Statistical table of detection results of human AMPH positive samples
[0069] As shown in Table 3, of the 10 positive samples detected by a foreign blot kit, 8 were positive; samples #9 and #10 had questionable or negative results. Among the truncated portions (full length), AMPH-1 (1-121 aa), AMPH-2 (122-250 aa), and AMPH-4 (401-550 aa) were all negative, indicating that this fragment is not a region containing an antigenic epitope; 6 AMPH-5 (551-695 aa) were positive and 4 were negative, indicating the presence of some antigenic epitopes; all of the full-length AMPH and AMPH-3 (251-400 aa) samples were positive, indicating that both the full-length AMPH and AMPH-3 have good sensitivity, and the AMPH-3 titer is significantly higher than that of the full-length AMPH, suggesting even higher sensitivity.
[0070] Depend on Figure 2 It is evident that the blot test kit can produce false negatives or questionable results. Some typical images show that sample #1 showed a strong positive (+++), sample #6 showed a weak positive (+), and sample #9 showed a questionable or negative result.
[0071] Depend on Figure 3Analysis of typical images of some positive samples revealed that, for positive samples #1, #6, and #10, the full-length AMPH assay showed that the positive cells were relatively round and lacked typical positive characteristics, making it difficult to interpret the positive signal. AMPH-3 showed high overall fluorescence intensity and the cells exhibited an antenna-like morphological characteristic, which was beneficial for interpreting the positive signal. The overall positive characteristics of AMPH-5 were similar to AMPH-3, but sample #10 tested negative, suggesting a false negative.
[0072] Based on the above results, the analysis shows that: AMPH-1, AMPH-2, and AMPH-4 fragments are non-antigenic epitope regions and are not suitable for detecting AMPH autoantibodies; the AMPH-5 fragment contains only a portion of the antigenic epitopes, resulting in insufficient detection sensitivity and a risk of false negatives; both the full-length AMPH and AMPH-3 fragments have good detection sensitivity, but the antibody titer of AMPH-3 is significantly higher than that of the full-length AMPH, and positive cells exhibit typical tentacle-like morphological characteristics, which is more conducive to the interpretation of positive signals. Therefore, the AMPH-3 (251-400 aa) fragment is the preferred antigenic region for AMPH autoantibody detection, but its specificity still needs further verification.
[0073] (2) AMPH negative sample test results (see Table 4 and Figure 4 ) Using a foreign blot kit and different AMPH truncated cell lines overexpressing AMPH, 13 AMPH-negative samples (physical examination samples from healthy individuals without obvious neurological symptoms or tumors) were tested based on the CBA methodology. The results are shown in Table 4.
[0074] Table 4. Statistical table of detection results of human AMPH negative samples
[0075] As shown in Table 4, a certain foreign blot kit showed negative results for all negative samples, indicating good specificity; while AMPH-3 and AMPH-5 had 2 positive samples (18# and 21#) and 1 positive sample (18#), respectively, indicating false positives and poor specificity.
[0076] Depend on Figure 4 Analysis of typical images of some negative samples showed that the AMPH-3 truncated protein fragment produced solid, round false-positive fluorescence in the CBA test results of samples 18# and 21#.
[0077] Based on the above results, it can be seen that the full-length AMPH, AMPH-3, and AMPH-5 truncated fragments showed varying degrees of false positive reactions in negative samples. Among them, AMPH-3 had the most false positive samples (18# and 21#, a total of 2 cases), followed by AMPH-5 (18#, a total of 1 case), indicating that the above truncated fragments are not specific enough when used as antigens for detection.
[0078] AMPH-1, AMPH-2, and AMPH-4 did not produce false positives in negative samples, but they also showed no detectable signal in positive samples (see Table 3), indicating that they are not suitable for detecting AMPH autoantibodies.
[0079] Based on the detection results of positive and negative samples in (I) and (II) above, AMPH-3, while exhibiting high sensitivity, suffers from false positives; AMPH-5 has insufficient sensitivity and exhibits both false negatives and false positives; and the full-length AMPH fragment has good sensitivity but a high risk of false positives. Therefore, it is necessary to further truncate the AMPH-3 fragment to screen for the optimal antigen fragment that combines high sensitivity and high specificity.
[0080] (3) Detection results of the truncated body on AMPH positive and negative samples (see Table 5 and Figure 5 ) Using a foreign blotting kit and overexpressing cell lines of AMPH-3-1, AMPH-3-2, and AMPH-3-3 truncated variants, 10 AMPH-positive samples (clinically presenting as stiff-person syndrome, encephalomyelitis, or sensory neuropathy, accompanied by small cell lung cancer or breast cancer) and 5 AMPH-negative samples (physical examination samples from healthy individuals without obvious neurological symptoms or tumors) were tested based on the CBA methodology. The results are shown in Table 5.
[0081] Table 5. Statistical table of AMPH positive and negative test results in human samples.
[0082] Note: In Tables 3 to 5, “(S)” refers to serum samples; “(C)” refers to cerebrospinal fluid samples.
[0083] Table 5 shows that the truncated fragments of AMPH-3-1 (251-310 aa), AMPH-3-2 (300-360 aa), and AMPH-3-3 (350-400 aa) are further segments of AMPH-3 (251-400 aa), and were detected using the CBA method with both positive and negative samples. As shown in Table 5, the AMPH-3-2 truncated protein fragments exhibit 100% sensitivity for positive samples. Negative sample detection showed that samples #18 and #21, which showed false positives for AMPH-3, did not show a signal in AMPH-3-2, indicating a significant improvement in specificity. False negatives or false positives were observed to varying degrees in both the AMPH-3-1 and AMPH-3-3 protein truncated fragments.
[0084] Depend on Figure 5 Analysis of typical images of some negative and positive samples showed that the AMPH-3-2 truncated protein fragment exhibited typical AMPH positive fluorescence colorimetric characteristics, while the non-specific colorimetric characteristics of samples 18# and 21# disappeared, and the negative background was clean and uniform, indicating good specificity and sensitivity.
[0085] Based on the above results, the analysis shows that: the AMPH-3-1 truncated variant has a low detection rate for positive samples (only 4 out of 10 positive samples were detected), exhibiting a serious false negative problem, and is not suitable for detecting AMPH autoantibodies; the AMPH-3-3 truncated variant has a high detection rate for positive samples, but still showed positive signals for 2 AMPH-3 false positive samples (18# and 21#) (both with a titer of 1:10), and tested negative for positive samples 2# and 6#, indicating a defect of both false positives and false negatives; the AMPH-3-2 truncated variant detected all 10 positive samples (sensitivity 100%), and did not show any signal for the two false positive samples 18# and 21# (significantly improved specificity), while the fluorescence color development showed typical tentacle-like positive morphological characteristics, with a clean and uniform background, which is conducive to the interpretation of positive signals. This indicates that the AMPH-3-2 truncated fragment is superior to AMPH-3-1 and AMPH-3-3 in terms of sensitivity, specificity, and signal interpretability, making it the optimal antigen fragment for AMPH autoantibody detection.
[0086] In summary, the AMPH-3-2 truncated variant (300-360 aa, as shown in SEQ ID NO: 11) provided by this invention exhibits a 100% detection rate for AMPH-positive samples in the CBA method, and shows no non-specific signal for negative samples with false positives for the AMPH-3 truncated variant. The fluorescence color development displays typical tentacle-like positive morphology characteristics with a clean and uniform background, demonstrating high sensitivity, high specificity, and good signal interpretability. Therefore, this truncated variant can serve as a specific recognition target for AMPH autoantibodies associated with paraneoplastic syndromes of the nervous system, providing reliable experimental evidence for the establishment of subsequent AMPH autoantibody detection methods and the development of clinical diagnostic reagents.
[0087] The above description is merely a preferred embodiment of the present invention and is not intended to limit the present invention in any way. Any simple modifications or equivalent changes made to the above embodiments based on the technical essence of the present invention shall fall within the protection scope of the present invention.
Claims
1. An AMPH-truncation protein for detecting amphipathic protein autoantibodies in neurological paraneoplastic syndromes, characterized in that: The AMPH truncated protein is a CLAP domain truncated variant of the AMPH protein, and its amino acid sequence is shown in SEQ ID NO:
11.
2. A nucleic acid molecule, characterized in that: The nucleic acid molecule encodes the AMPH truncated protein of claim 1.
3. A recombinant expression vector, characterized in that: The recombinant expression vector comprises the nucleic acid molecule as described in claim 2.
4. A recombinant host cell, characterized in that: The recombinant host cell comprises the recombinant expression vector of claim 3, or the nucleic acid molecule of claim 2 is integrated into the chromosome.
5. The use of the AMPH truncated protein as described in claim 1 in the preparation of diagnostic reagents for detecting amphipathic protein autoantibodies in paraneoplastic syndromes of the nervous system, characterized in that: The diagnostic reagent detects autoantibodies against amphoteric proteins using a cell substrate method.
6. The application according to claim 5, characterized in that: The paraneoplastic syndrome of the nervous system includes one or more of stiff-person syndrome, encephalomyelitis, or peripheral neuropathy.
7. A kit for detecting amphipathic protein autoantibodies in paraneoplastic syndromes of the nervous system, characterized in that: It contains the AMPH truncation protein as described in claim 1.
8. The reagent kit according to claim 7, characterized in that: The kit detects autoantibodies against amphipathic proteins using a cell substrate method.
